BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 19074844)

  • 1. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.
    Ma J; Waxman DJ
    Mol Cancer Ther; 2008 Dec; 7(12):3670-84. PubMed ID: 19074844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Close A
    Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic therapy for cancer: an update.
    Al-Husein B; Abdalla M; Trepte M; Deremer DL; Somanath PR
    Pharmacotherapy; 2012 Dec; 32(12):1095-111. PubMed ID: 23208836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy for cancer: current and emerging concepts.
    Jain RK
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
    Jain RK
    Science; 2005 Jan; 307(5706):58-62. PubMed ID: 15637262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of antiangiogenic therapies.
    Hudis CA
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):26-31. PubMed ID: 15934500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and future directions for angiogenesis-based cancer therapies.
    Scappaticci FA
    J Clin Oncol; 2002 Sep; 20(18):3906-27. PubMed ID: 12228212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly discovered angiogenesis inhibitors and their mechanisms of action.
    Miao ZH; Feng JM; Ding J
    Acta Pharmacol Sin; 2012 Sep; 33(9):1103-11. PubMed ID: 22922347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenic inhibitors: a new therapeutic strategy in oncology.
    Gasparini G; Longo R; Toi M; Ferrara N
    Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
    Loges S; Mazzone M; Hohensinner P; Carmeliet P
    Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
    Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
    Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The possible role of chemotherapy in antiangiogenic drug resistance.
    Bocci G; Loupakis F
    Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic agents in cancer therapy.
    Lenz HJ
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy.
    Blagosklonny MV
    Cancer Biol Ther; 2005 Dec; 4(12):1307-10. PubMed ID: 16322683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
    Bottsford-Miller JN; Coleman RL; Sood AK
    J Clin Oncol; 2012 Nov; 30(32):4026-34. PubMed ID: 23008289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.